Equities analysts predict that Nevro Corp (NYSE:NVRO) will announce earnings of ($0.76) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Nevro’s earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.96). Nevro reported earnings of ($0.32) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 137.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, February 20th.
According to Zacks, analysts expect that Nevro will report full year earnings of ($3.75) per share for the current year, with EPS estimates ranging from ($4.26) to ($3.49). For the next year, analysts expect that the firm will report earnings of ($2.96) per share, with EPS estimates ranging from ($3.78) to ($1.41). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Nevro.
Nevro (NYSE:NVRO) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.27. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The firm had revenue of $100.16 million for the quarter, compared to the consensus estimate of $92.27 million. During the same period in the prior year, the business posted ($0.37) earnings per share. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year.
Nevro stock traded down $0.21 during trading on Friday, reaching $113.14. The company had a trading volume of 306,700 shares, compared to its average volume of 513,159. Nevro has a 12-month low of $34.75 and a 12-month high of $114.76. The company has a debt-to-equity ratio of 0.91, a quick ratio of 4.54 and a current ratio of 5.87. The stock’s 50 day moving average price is $98.89 and its two-hundred day moving average price is $78.95. The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of -68.99 and a beta of 0.30.
In other news, Director Shawn Mccormick sold 800 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $104.35, for a total value of $83,480.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Doug Alleavitch sold 1,000 shares of Nevro stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $100.00, for a total transaction of $100,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,322 shares of company stock worth $3,538,891. 7.60% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in NVRO. Metropolitan Life Insurance Co NY raised its position in Nevro by 4.0% in the third quarter. Metropolitan Life Insurance Co NY now owns 9,651 shares of the medical equipment provider’s stock valued at $830,000 after purchasing an additional 367 shares during the period. Man Group plc grew its stake in shares of Nevro by 181.9% in the third quarter. Man Group plc now owns 24,071 shares of the medical equipment provider’s stock valued at $2,070,000 after buying an additional 15,533 shares in the last quarter. Redmile Group LLC raised its holdings in shares of Nevro by 18,837.2% during the 3rd quarter. Redmile Group LLC now owns 643,864 shares of the medical equipment provider’s stock valued at $55,353,000 after buying an additional 640,464 shares during the period. Voloridge Investment Management LLC purchased a new stake in shares of Nevro during the 3rd quarter valued at about $2,109,000. Finally, Point72 Asset Management L.P. lifted its position in Nevro by 49.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 221,954 shares of the medical equipment provider’s stock worth $19,081,000 after acquiring an additional 73,578 shares in the last quarter.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Recommended Story: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.